DE2425988A1 - Medikament zur bekaempfung von erregungsund angstsyndromen - Google Patents
Medikament zur bekaempfung von erregungsund angstsyndromenInfo
- Publication number
- DE2425988A1 DE2425988A1 DE19742425988 DE2425988A DE2425988A1 DE 2425988 A1 DE2425988 A1 DE 2425988A1 DE 19742425988 DE19742425988 DE 19742425988 DE 2425988 A DE2425988 A DE 2425988A DE 2425988 A1 DE2425988 A1 DE 2425988A1
- Authority
- DE
- Germany
- Prior art keywords
- acid
- drug
- amphetamine
- medicament according
- combat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims description 14
- 229940079593 drug Drugs 0.000 title claims description 6
- 208000011580 syndromic disease Diseases 0.000 title claims description 6
- 230000005284 excitation Effects 0.000 title 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 19
- 229940114079 arachidonic acid Drugs 0.000 claims description 10
- 235000021342 arachidonic acid Nutrition 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 150000003180 prostaglandins Chemical class 0.000 claims description 9
- 230000037007 arousal Effects 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 235000004626 essential fatty acids Nutrition 0.000 claims description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 229940025084 amphetamine Drugs 0.000 description 12
- OFIDNKMQBYGNIW-UHFFFAOYSA-N arachidonic acid methyl ester Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC OFIDNKMQBYGNIW-UHFFFAOYSA-N 0.000 description 12
- OFIDNKMQBYGNIW-ZKWNWVNESA-N methyl arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC OFIDNKMQBYGNIW-ZKWNWVNESA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 150000003943 catecholamines Chemical class 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000037023 motor activity Effects 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 229960000632 dexamfetamine Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 101150002688 kremen1 gene Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KZBKRARRXDZOII-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;2-hydroxybenzoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)C1=CC=CC=C1O KZBKRARRXDZOII-ZSCHJXSPSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2575073A GB1476624A (en) | 1973-05-30 | 1973-05-30 | Tranquiliser medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2425988A1 true DE2425988A1 (de) | 1974-12-19 |
Family
ID=10232682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742425988 Withdrawn DE2425988A1 (de) | 1973-05-30 | 1974-05-30 | Medikament zur bekaempfung von erregungsund angstsyndromen |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE2425988A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2231379B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1476624A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3325130A1 (de) * | 1983-06-29 | 1985-01-03 | Pierre-Richard Nizza Dick | Pharmazeutische zusammensetzung zur anwendung fuer die haut auf der basis von essentiellen fettsaeuren und diese enthaltende vorrichtung |
| US5043328A (en) * | 1986-05-09 | 1991-08-27 | Hoechst Aktiengesellschaft | Formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems |
| EP0567216A1 (en) * | 1992-04-08 | 1993-10-27 | Transcend Therapeutics, Inc. | Composition comprising omega-3 fatty acid source and glutathione stimulator for the treatment of immunedisorders and viral infections |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU527784B2 (en) * | 1978-05-26 | 1983-03-24 | Bang, Hans Olaf Dr. | Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid |
| DE3366506D1 (en) * | 1982-03-01 | 1986-11-06 | Efamol Ltd | Pharmaceutical composition |
| NZ205076A (en) * | 1982-08-09 | 1985-04-30 | Univ California | Protecting and healing gastro-duodenal mucosa and the liver of mammals using a fatty acid |
| IL69782A (en) * | 1982-09-22 | 1987-12-20 | Sentrachem Ltd | Compositions for preventing cancerous conditions comprising precursors of eicosanoid mixtures and a dietary supplement containing them |
| GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
| GB8319073D0 (en) * | 1983-07-14 | 1983-08-17 | Efamol Ltd | Fatty acid compositions |
| CA1239587A (en) * | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
| FR2573653B1 (fr) * | 1984-11-23 | 1988-02-26 | Pf Medicament | Compositions pharmaceutiques antiandrogenes a base d'acides gras |
| FR2581310B1 (fr) * | 1985-05-02 | 1988-09-23 | Natura Medica Laboratoires | Composition therapeutique comportant de l'acide a-linolenique et un compose susceptible de favoriser le passage de l'acide au travers de la membrane cellulaire et extrait de plantes comprenant l'acide et le compose |
| DE3719097C1 (de) * | 1987-06-06 | 1988-06-09 | Fratzer Uwe | Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| US7485743B2 (en) | 2004-07-20 | 2009-02-03 | Btg International Limited | Oligomeric ketone compounds |
-
1973
- 1973-05-30 GB GB2575073A patent/GB1476624A/en not_active Expired
-
1974
- 1974-05-21 FR FR7417692A patent/FR2231379B1/fr not_active Expired
- 1974-05-30 DE DE19742425988 patent/DE2425988A1/de not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3325130A1 (de) * | 1983-06-29 | 1985-01-03 | Pierre-Richard Nizza Dick | Pharmazeutische zusammensetzung zur anwendung fuer die haut auf der basis von essentiellen fettsaeuren und diese enthaltende vorrichtung |
| US5043328A (en) * | 1986-05-09 | 1991-08-27 | Hoechst Aktiengesellschaft | Formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems |
| EP0567216A1 (en) * | 1992-04-08 | 1993-10-27 | Transcend Therapeutics, Inc. | Composition comprising omega-3 fatty acid source and glutathione stimulator for the treatment of immunedisorders and viral infections |
Also Published As
| Publication number | Publication date |
|---|---|
| GB1476624A (en) | 1977-06-16 |
| FR2231379A1 (enrdf_load_stackoverflow) | 1974-12-27 |
| FR2231379B1 (enrdf_load_stackoverflow) | 1977-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60000133T2 (de) | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen | |
| DE69315020T2 (de) | Verwendung von Fettsäuren zur Erhöhung der Calciumabsorption im Darm | |
| DE68911103T2 (de) | Verwendung von Fettsäuren zur Behandlung von myalgischer Enzephalomyelitis. | |
| DE4133694C2 (de) | Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen | |
| EP0267321B1 (de) | Ibuprofen enthaltendes Arzneimittel | |
| DE60130023T2 (de) | Behandlung der nebenwirkungen von statinen | |
| DE69720787T2 (de) | Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure | |
| DE2425988A1 (de) | Medikament zur bekaempfung von erregungsund angstsyndromen | |
| DE3005208A1 (de) | Verwendung von acylcarnitin in arzneimitteln zur behandlung von stoerungen im gehirn-metabolismus | |
| DE2818553A1 (de) | Zusammensetzung zur behandlung von proliferativen hautkrankheiten | |
| DE69908304T2 (de) | Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen | |
| DE60132008T2 (de) | Cetylmyristat und cetylpalmitat zur behandlung von ekzemen und/oder psoriasis | |
| DE69005062T2 (de) | Fettsäuren zur Behandlung und Prävention von Hautschäden durch Radiotherapie. | |
| US5516801A (en) | Fatty acid treatment for ectopic calcium deposition | |
| DE69317716T2 (de) | Verwendung von Fettsäuren zur Behandlung von abnormalen Verkalkung des Gewebes | |
| DE69429823T2 (de) | Verwendung von stickstoffoxid-synthase-substrat und/oder -donor oder stickstoffoxidhemmer zur herstellung von medikamenten zur behandlung von störungen der uterinen kontraktilität | |
| DE3344173C2 (de) | Verwendung von alkanoyl-l-carnitin zur behandlung von myopathien oder muskulaeren dystrophien | |
| DE4022815A1 (de) | Topische verwendung von (omega)-3-fettsaeuren-zubereitungen fuer hauterkrankungen | |
| DE2640322A1 (de) | Medizinische zubereitung mit einem gehalt an nebennierenrindenhormon und einem ein schilddruesenstimulierendes hormon freisetzenden hormon | |
| DE3875637T2 (de) | Zusammensetzungen und verfahren zur behandlung von magengeschwueren. | |
| EP1001756A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE69325512T2 (de) | Verwendung von remacemid zur behandlung des morbus parkinson | |
| DE10301917B4 (de) | Verwendung von Substanzen der Porphyrinsynthese bei der Phototherapie von Haut- oder Gelenkerkrankungen des Menschen oder von Säugetieren | |
| DE19629802A1 (de) | Arzneimittel zur Behandlung von Neuropathien | |
| DE2831728C2 (de) | Arzneimittel zur Behandlung von Kopfschmerzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |